関連レポート

出版元：Transparency Market Research  出版元について

発行年：2024年4月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 143ページになります。

商品コード：TMR260

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

慢性腎臓病治療薬の世界市場規模は2023年で148億ドル、2034年に238億ドル、市場の平均年成長率は4.2%にて増加する見込みです。

当レポートでは、慢性腎臓病治療薬の市場予測-2034年、各種セグメント別市場分析(薬剤クラス別、エンドユーザー別、国地域別、等)、パイプライン分析、主要製品/ブランド分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■慢性腎臓病治療薬の世界市場予測2020-2034年
・市場規模(US$)

■薬剤クラス別、市場-2034年
・ACE阻害薬
・アンジオテンシンII受容体拮抗薬
・カルシウム拮抗薬
・β遮断薬
・赤血球造血刺激因子製剤（ESA）
・利尿薬
・その他
※(市場規模US$)　

■エンドユーザー別、市場-2034年
・病院
・専門クリニック
※(市場規模US$)　

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス
パイプライン分析
主要製品/ブランド分析
主要な合併、買収

■慢性腎臓病治療薬の主要企業プロフィール動向
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi
GSK plc
キッセイ薬品工業株式会社
AbbVie Inc.
Akebia Therapeutics, Inc.
AstraZeneca
Amgen Inc.
Teva Pharmaceutical Industries Ltd.

（全143頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Chronic Kidney Disease (CKD) Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. ACE Inhibitors
6.3.2. Angiotensin-II Receptor Blockers
6.3.3. Calcium Channel Blockers
6.3.4. Beta Blockers
6.3.5. Erythropoiesis-stimulating Agents (ESAs)
6.3.6. Diuretics
6.3.7. Others
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2020-2034
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.4. Market Attractiveness Analysis, by End-user

8. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region

9. North America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Drug Class, 2020-2034
9.3.1. ACE Inhibitors
9.3.2. Angiotensin-II Receptor Blockers
9.3.3. Calcium Channel Blockers
9.3.4. Beta Blockers
9.3.5. Erythropoiesis-stimulating Agents (ESAs)
9.3.6. Diuretics
9.3.7. Others
9.4. Market Value Forecast, by End-user, 2020-2034
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By End-user
9.6.3. By Country

10. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
10.3.1. ACE Inhibitors
10.3.2. Angiotensin-II Receptor Blockers
10.3.3. Calcium Channel Blockers
10.3.4. Beta Blockers
10.3.5. Erythropoiesis-stimulating Agents (ESAs)
10.3.6. Diuretics
10.3.7. Others
10.4. Market Value Forecast, by End-user, 2020-2034
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By End-user
10.6.3. By Country/Sub-region

11. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. ACE Inhibitors
11.3.2. Angiotensin-II Receptor Blockers
11.3.3. Calcium Channel Blockers
11.3.4. Beta Blockers
11.3.5. Erythropoiesis-stimulating Agents (ESAs)
11.3.6. Diuretics
11.3.7. Others
11.4. Market Value Forecast, by End-user, 2020-2034
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By End-user
11.6.3. By Country/Sub-region

12. Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
12.3.1. ACE Inhibitors
12.3.2. Angiotensin-II Receptor Blockers
12.3.3. Calcium Channel Blockers
12.3.4. Beta Blockers
12.3.5. Erythropoiesis-stimulating Agents (ESAs)
12.3.6. Diuretics
12.3.7. Others
12.4. Market Value Forecast, by End-user, 2020-2034
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By End-user
12.6.3. By Country/Sub-region

13. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. ACE Inhibitors
13.3.2. Angiotensin-II Receptor Blockers
13.3.3. Calcium Channel Blockers
13.3.4. Beta Blockers
13.3.5. Erythropoiesis-stimulating Agents (ESAs)
13.3.6. Diuretics
13.3.7. Others
13.4. Market Value Forecast, by End-user, 2020-2034
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By End-user
13.6.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. F. Hoffmann-La Roche Ltd.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Pfizer, Inc.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Sanofi
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. GSK plc
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Kissei Pharmaceutical Co., Ltd.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. AbbVie Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Akebia Therapeutics, Inc.
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. AstraZeneca
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Amgen Inc.
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Teva Pharmaceutical Industries Ltd.
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview

List of Tables

Table 01: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 02: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 03: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Region, 2020-2034

Table 04: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2020-2034

Table 05: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 06: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 07: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 08: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 09: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 10: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 11: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 12: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 13: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 14: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 15: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 16: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 17: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 18: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

Figure 01: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global Chronic Kidney Disease (CKD) Drugs Market Revenue (US$ Mn), by Drug Class, 2023

Figure 03: Global Chronic Kidney Disease (CKD) Drugs Market Value Share, by Drug Class, 2023

Figure 04: Global Chronic Kidney Disease (CKD) Drugs Market Revenue (US$ Mn), by End-user, 2023

Figure 05: Global Chronic Kidney Disease (CKD) Drugs Market Value Share, by End-user, 2023

Figure 06: Global Chronic Kidney Disease (CKD) Drugs Market Value Share, by Region, 2023

Figure 07: Global Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast, 2020-2034

Figure 08: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 09: Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 10: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034

Figure 11: Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034

Figure 12: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region, 2023 and 2034

Figure 13: Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Region, 2024-2034

Figure 14: North America Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 15: North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country, 2024-2034

Figure 16: North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country, 2023 and 2034

Figure 17: North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 18: North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034

Figure 19: North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 20: North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034

Figure 21: Europe Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 22: Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 23: Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 24: Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 25: Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034

Figure 26: Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 27: Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034

Figure 28: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 29: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 30: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 31: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 32: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034

Figure 33: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 34: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034

Figure 35: Latin America Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 36: Latin America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 37: Latin America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 38: Latin America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 39: Latin America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034

Figure 40: Latin America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 41: Latin America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034

Figure 42: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 43: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 44: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 45: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 46: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034

Figure 47: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 48: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034

△ 一番上に戻る